University of Queensland Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia.
Leukemia. 2013 Feb;27(2):269-77. doi: 10.1038/leu.2012.225. Epub 2012 Aug 9.
The Myb protein was first identified as an oncogene that causes leukemia in chickens. Since then, it has been widely associated with different types of cancers and studied in detail in myeloid leukemias. However, despite these studies, its role in the induction, pathogenesis and maintenance of AML, and other blood disorders, is still not well understood. Recent efforts to uncover its plethora of transcriptional targets have provided key insights into understanding its mechanism of action. This review evaluates our current knowledge of the role of Myb in leukemia, with a particular focus on AML, from the vast literature spanning three decades, highlighting key studies that have influenced our understanding. We discuss recent insights into its role in leukemogenesis and how these could be exploited for the therapeutic targeting of Myb, its associated co-regulators or its target genes, in order to improve outcomes in the treatment of a wide range of hematopoietic malignancies.
Myb 蛋白最初被鉴定为一种致癌基因，可导致鸡的白血病。此后，它与不同类型的癌症广泛相关，并在髓性白血病中进行了详细研究。然而，尽管进行了这些研究，但它在诱导、发病机制和维持 AML 及其他血液疾病中的作用仍未得到很好的理解。最近，为了揭示其众多的转录靶标，人们做出了巨大的努力，这为理解其作用机制提供了关键的见解。这篇综述评估了我们目前对 Myb 在白血病中的作用的认识，特别是对 AML 的认识，从跨越三十年的大量文献中，突出了影响我们理解的关键研究。我们讨论了其在白血病发生中的作用的最新见解，以及如何利用这些见解来靶向 Myb、其相关共调节剂或其靶基因进行治疗，以改善广泛的造血恶性肿瘤的治疗效果。
